Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients

HIV infection modifies the course of hepatitis C virus (HCV) disease, and chronic HCV infection is becoming a growing cause of morbidity and mortality in coinfected patients. The rate of response to interferon (IFN)- alpha may be lower in HIV-positive patients with chronic HCV. Furthermore, it is no...

Full description

Saved in:
Bibliographic Details
Published inAIDS (London) Vol. 13; no. 1; pp. 140 - 141
Main Authors UBERTI-FOPPA, C, DE BONA, A, MORSICA, G, GUFFANTI, M, GIANOTTI, N, BOERI, E, LAZZARIN, A
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 14.01.1999
Subjects
AIDS-Related Opportunistic Infections - drug therapy
AIDS-Related Opportunistic Infections - immunology
AIDS-Related Opportunistic Infections - virology
AIDS/HIV
Biological and medical sciences
Hepatitis C - drug therapy
Hepatitis C - immunology
Hepatitis C - virology
Hepatitis C virus
Human immunodeficiency virus 1
Human viral diseases
Humans
Infectious diseases
Interleukin-2 - therapeutic use
Medical sciences
Recombinant Proteins - therapeutic use
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
Human
Immunopathology
Mixed infection
Treatment efficiency
Cytokine
Hepatic disease
AIDS
Immune deficiency
Infection
Chemotherapy
Association
Treatment
Interleukin 2
Viral disease
Digestive diseases
Antiviral
Viral hepatitis C
Online AccessGet full text

Cover

More Information
Summary:HIV infection modifies the course of hepatitis C virus (HCV) disease, and chronic HCV infection is becoming a growing cause of morbidity and mortality in coinfected patients. The rate of response to interferon (IFN)- alpha may be lower in HIV-positive patients with chronic HCV. Furthermore, it is not well known how IFN- alpha therapy could modify the natural history of HIV infection. We observed a reduction of HCV viral load after treatment with intermittent recombinant interleukin-2 (rIL-2). This therapy is capable of inducing marked sustained increases of CD4 cell counts in HIV-positive patients with greater than 200X10 super(6) cells/1. In our institute, an ongoing randomized phase II study has being conducted since 1996 in order to compare three active rIL-2 treatment arms associated with antiretroviral therapy versus antiretroviral therapy alone in patients with CD4 cell counts of 200-500X10 super(6)/1.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0269-9370
1473-5571